Terms: = Thyroid cancer AND PIK3CA, MGC142161, 5290, ENSG00000121879, P42336, MGC142163, p110-alpha, PI3K
702 results:
1. Biological functions of LncRNA SNHG14 in the development of thyroid cancer cells via targeting miR-206.
Sang Y; Min R; Huang T; Zhang J
Cell Mol Biol (Noisy-le-grand); 2024 Apr; 70(4):77-84. PubMed ID: 38678623
[TBL] [Abstract] [Full Text] [Related]
2. The emerging role and clinical significance of circRNAs in papillary thyroid cancer.
Ma J; Xu J; Zhang X; Quan J
Front Endocrinol (Lausanne); 2024; 15():1351776. PubMed ID: 38544689
[TBL] [Abstract] [Full Text] [Related]
3. Osteopontin promotes tumor growth and metastasis and GPX4-mediated anti-lipid peroxidation in triple-negative breast cancer by activating the pi3k/Akt/mTOR pathway.
Guo M; Liu M; Li W; Wang C; Zhang L; Zhang H
J Cancer Res Clin Oncol; 2024 Mar; 150(3):155. PubMed ID: 38526702
[TBL] [Abstract] [Full Text] [Related]
4. Morusin inhibits breast cancer-induced osteolysis by decreasing phosphatidylinositol 3-kinase (pi3k)-mTOR signalling.
Zhang L; Li W; Chen X; Cao D; You S; Shi F; Luo Z; Li H; Zeng X; Song Y; Li N; Akimoto Y; Rui G; Chen Y; Wu Z; Xu R
Chem Biol Interact; 2024 May; 394():110968. PubMed ID: 38522564
[TBL] [Abstract] [Full Text] [Related]
5. CD93 regulates breast cancer growth and vasculogenic mimicry through the pi3k/AKT/SP2 signaling pathway activated by integrin β1.
Liu H; Zhang J; Zhao Y; Fan Z; Yang Y; Mao Y; Yang J; Ma S
J Biochem Mol Toxicol; 2024 Apr; 38(4):e23688. PubMed ID: 38511888
[TBL] [Abstract] [Full Text] [Related]
6. Bioinformatics analysis for the identification of Sprouty-related EVH1 domain-containing protein 3 expression and its clinical significance in thyroid carcinoma.
Zhang X; Meng X; Wang P; Luan C; Wang H
Sci Rep; 2024 Feb; 14(1):4549. PubMed ID: 38402263
[TBL] [Abstract] [Full Text] [Related]
7. Deep response to a combination of mTOR inhibitor temsirolimus and dual immunotherapy of nivolumab/ipilimumab in poorly differentiated thyroid carcinoma with
Oh Y; Park JH; Djunadi TA; Shah Z; Chung LI; Chae YK
Front Endocrinol (Lausanne); 2024; 15():1304188. PubMed ID: 38356955
[TBL] [Abstract] [Full Text] [Related]
8. GBP2 enhances paclitaxel sensitivity in triple‑negative breast cancer by promoting autophagy in combination with ATG2 and inhibiting the pi3k/AKT/mTOR pathway.
Zhang W; Tang X; Peng Y; Xu Y; Liu L; Liu S
Int J Oncol; 2024 Apr; 64(4):. PubMed ID: 38334171
[TBL] [Abstract] [Full Text] [Related]
9. Bioinformatics analysis identifies coagulation factor II receptor as a potential biomarker in stomach adenocarcinoma.
Wu X; Wang S; Wang C; Wu C; Zhao Z
Sci Rep; 2024 Jan; 14(1):2468. PubMed ID: 38291086
[TBL] [Abstract] [Full Text] [Related]
10. GLP-1 receptor agonist liraglutide inhibits the proliferation and migration of thyroid cancer cells.
Zhang X; Zhang L; Wang B; Zhang X; Gu L; Guo K; Zhang X; Zhou Z
Cell Mol Biol (Noisy-le-grand); 2023 Dec; 69(14):221-225. PubMed ID: 38279433
[TBL] [Abstract] [Full Text] [Related]
11. Genetic alterations in thyroid cancer mediating both resistance to BRAF inhibition and anaplastic transformation.
Lee M; Morris LG
Oncotarget; 2024 Jan; 15():36-48. PubMed ID: 38275291
[TBL] [Abstract] [Full Text] [Related]
12. A phase 1 study of triple-targeted therapy with BRAF, MEK, and AKT inhibitors for patients with BRAF-mutated cancers.
Algazi AP; Moon J; Lao CD; Chmielowski B; Kendra KL; Lewis KD; Gonzalez R; Kim K; Godwin JE; Curti BD; Latkovic-Taber M; Lomeli SH; Gufford BT; Scumpia PO; Lo RS; Othus M; Ribas A
Cancer; 2024 May; 130(10):1784-1796. PubMed ID: 38261444
[TBL] [Abstract] [Full Text] [Related]
13. Evaluation of the Therapeutic Effects of Harmine on Anaplastic thyroid cancer Cells.
Baldini E; Cardarelli S; Campese AF; Lori E; Fallahi P; Virili C; Forte F; Pironi D; Di Matteo FM; Palumbo P; Costanzo ML; D'Andrea V; Centanni M; Sorrenti S; Antonelli A; Ulisse S
Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38256193
[TBL] [Abstract] [Full Text] [Related]
14. CCDC86 promotes the aggressive behavior of nasopharyngeal carcinoma by positively regulating EGFR and activating the pi3k/Akt signaling.
Wang Z; Zhou T; Chen X; Zhu X; Liao B; Liu J; Li S; Tan T; Liu Y
Neoplasma; 2023 Dec; 70(6):761-776. PubMed ID: 38247332
[TBL] [Abstract] [Full Text] [Related]
15. The immune checkpoint TIGIT/CD155 promotes the exhaustion of CD8 + T cells in TNBC through glucose metabolic reprogramming mediated by pi3k/AKT/mTOR signaling.
Huang M; Yu X; Wang Q; Jiang Z; Li X; Chen W; Song C
Cell Commun Signal; 2024 Jan; 22(1):35. PubMed ID: 38216949
[TBL] [Abstract] [Full Text] [Related]
16. HDAC inhibitors target IRS4 to enhance anti‑AR therapy in AR‑positive triple‑negative breast cancer.
He Y; Ma Y; Zhu Y; Zhang J; Zhao S; Zhang D; Xu D; Li Y; Tong Z; Zhao W
Int J Oncol; 2024 Mar; 64(3):. PubMed ID: 38214343
[TBL] [Abstract] [Full Text] [Related]
17. EPYC functions as a novel prognostic biomarker for pancreatic cancer.
Yang Z; Li H; Hao J; Mei H; Qiu M; Wang H; Gao M
Sci Rep; 2024 Jan; 14(1):719. PubMed ID: 38184732
[TBL] [Abstract] [Full Text] [Related]
18. IRS1 promotes thyroid cancer metastasis through EMT and pi3k/AKT pathways.
Yu F; Huang D; Kuang Y; Dong J; Han Q; Zhou J; Teng X
Clin Endocrinol (Oxf); 2024 Mar; 100(3):284-293. PubMed ID: 38172081
[TBL] [Abstract] [Full Text] [Related]
19. TIROSEC: Molecular, Clinical and Histopathological Profile of Papillary thyroid Carcinoma in a Colombian Cohort.
Cruz-Romero SD; González S; Juez JY; Becerra DS; Baldión AM; Hakim JA; González-Devia D; Perdomo S; Rodríguez-Urrego PA
Adv Ther; 2024 Feb; 41(2):792-805. PubMed ID: 38170436
[TBL] [Abstract] [Full Text] [Related]
20. Pancreatic cancer stem cell-derived exosomal miR-210 mediates macrophage M2 polarization and promotes gemcitabine resistance by targeting FGFRL1.
Guo Y; Cui J; Liang X; Chen T; Lu C; Peng T
Int Immunopharmacol; 2024 Jan; 127():111407. PubMed ID: 38134594
[TBL] [Abstract] [Full Text] [Related]
[Next]
